EN DE
Watch Trident Lifeline Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Trident Lifeline Ltd (TLL) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Trident Lifeline Ltd stock ₹271, price ₹410, that is 33.9% below the price, quality 39 out of 100. Rating: overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE0MKA01014

TL Trident Lifeline Ltd logo Some data Nov 17, 2026

Trident Lifeline Ltd

TLL · BSE

Expensive (fair value 34% below the price) and weak company, but rising price: meets 1 of 3 rules.

Follow free in the weekly email
Rising price (uptrend) 
Solidly profitable · 15.1% net margin (TTM) 
Low debt 
Last quarter vs. a year ago: revenue +43%, profit +75%. 
Expensive Growth (revenue 5y +68.1 %/yr in INR) 
Mixed vs. peers (5/12) 
Moderate moat 64/100 · thin data
Some data 
Fair value ₹271.05 · Overvalued 
Quality 39/100 
Negative free cash flow 
Watch Trident Lifeline Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹434.50 ₹108.15 Fair Value ₹271.05 Oct 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

49‑month range ₹108.15 – ₹434.50 · fair‑value band ₹202.64 – ₹353.16 · the ₹410.00 price screens above the ₹271.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Trident Lifeline in your weekly email

Every Wednesday you see whether Trident Lifeline is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Trident Lifeline Limited, a pharmaceutical company, engages in the manufacture and marketing of finished dosages in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally.

Show moreShow less

It offers pharmaceutical products in the form of tablets, capsules, liquid orals, external preparations, gel, mouthwash, and lotion; and nutraceutical tablets, capsules, liquids, sachets, oral sprays, and effervescent tablets, as well as ice gels, pastes, solutions, suspension, syrup, cream, drypowders, and toothpastes.

The company was incorporated in 2014 and is based in Surat, India.

Stock analysis

Trident Lifeline Ltd (TLL) currently trades at ₹410.00, while our model-based Fair Value estimate is ₹271.05, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹738.39 per share, and 4 of the 14 models we run sit above the ₹410.00 price.

Bear case: the Economic Profit group reads lowest at ₹78.89, and 10 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ₹202.64 (bear) to ₹353.16 (bull), the price of ₹410.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Trident Lifeline Ltd reported revenue of ₹1.3B in FY2026 versus ₹218M in FY2022, a compound +56.0%/yr. Reported net income was ₹190M in FY2026, compounding +48.2%/yr from FY2022.

Key figures

Market cap ₹4.9B (≈ $52.3M) Micro · P/E ratio 22.9 · P/S ratio 3.52 · EPS (TTM) ₹17.93 · Net margin 15.1% · Return on equity 21.8% · Return on assets (EBIT) 10.7% (5-year average) · Operating margin 20.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 64 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 72% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 20% fair-value upside, at −34%, TLL screens richer than that median.

Fair Value models

Bear ₹202.64 Fair Value ₹271.05 Bull ₹353.16
Price ₹410.00 · Downside -33.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹11.45 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV ₹56.37 ₹64.79 ₹71.39 71
ROIC Compounder ₹56.37 ₹64.79 ₹71.39 70
Residual Income ₹76.38 ₹92.98 ₹130.26 68
All 14 models by family
Earnings-Based
Graham-Dodd ₹108.07 ₹753.68 ₹1,058 61
Lynch FV ₹389.38 ₹556.25 ₹723.13 59
PEG = 1.0 ₹389.38 ₹556.25 ₹723.13 55
EPV ₹56.37 ₹64.79 ₹71.39 71
Multiples
P/E Multiple ₹262.23 ₹349.65 ₹437.06 63
P/S Multiple ₹202.64 ₹270.18 ₹337.73 58
P/B Multiple ₹225.31 ₹300.42 ₹375.52 55
EV/EBIT ₹177.17 ₹255.35 ₹333.54 65
EV/EBITDA ₹188.94 ₹271.05 ₹353.16 67
EV/Revenue ₹110.02 ₹181.76 ₹253.51 52
Asset-Based
NCAV (Graham) ₹1.70 ₹2.58 ₹3.22 55
Economic Profit
Residual Income ₹76.38 ₹92.98 ₹130.26 68
ROIC Compounder ₹56.37 ₹64.79 ₹71.39 70
Growth Earnings
Growth-Adj P/E ₹516.87 ₹738.39 ₹959.91 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 53
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 53
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 65
How calm the share price moves, does not count
Price momentum 89
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 78
Distance to the 52-week high, does not count
New shares 57
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+48.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+59.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+68.1%
Start year 2021 (pandemic)
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+56.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+56.2%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 17%
2026 sits 189% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

TLL screens overvalued: fair value 34% below the price. Compare with JD Health International Inc →

Compare Trident Lifeline Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 55 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −33.9% · Bottom 25%
Profitability
Return on equity (12 months) 21.8% · Top 25%
Return on assets 8.0% · Top 25%
Net margin (12 months) 15.1% · Top 25%
Operating margin (12 months) 20.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 42.8% · Top 25%
Balance sheet
Debt / equity 0.40× · Highest 25%

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/E (12 months) 22.9× · Pricier than median
P/B 4.87× · Priciest 25%
P/S (12 months) 3.52× · Priciest 25%
EV/EBITDA 16.7× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 59
FUTURE (revenue growth)100 · sector 26
PAST (return on equity)87 · sector 25
HEALTH (low debt)80 · sector 95
DIVIDEND (yield)0 · sector 53

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
JD Health International Inc 6618 HK$32.42 HK$75.43 +133% vs TLL
Yifeng Pharmacy Chain Co 603939 ¥26.50 ¥40.59 +53% vs TLL
Yixintang Pharmaceutical Group 002727 ¥13.10 ¥18.92 +44% vs TLL
DaShenLin Pharmaceutical Group 603233 ¥20.76 ¥25.52 +23% vs TLL
Nahdi Medical Company 4164 94.05 SAR 113.21 SAR +20% vs TLL
Anhui Huaren Health Pharmaceutical Co 301408 ¥12.08 ¥13.85 +15% vs TLL
LBX Pharmacy Chain Joint Stock Company 603883 ¥14.63 ¥16.40 +12% vs TLL
DocMorris AG DOCM CHF 18.80 CHF 15.17 −19% vs TLL
ShuYu Civilian Pharmacy Corp 301017 ¥10.76 ¥5.91 −45% vs TLL
Apotea AB APOTEA kr 101.50 kr 39.50 −61% vs TLL

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Trident Lifeline Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Trident Lifeline Ltd Fair Value". https://www.fairvalue-calculator.com/stock/TLL

Frequently asked questions

Is Trident Lifeline Ltd (TLL) overvalued or undervalued?
As of Nov 17, 2026, our model estimates a fair value of ₹271.05 versus a price of ₹410.00, about 34% lower (overvalued).
What is the fair value of TLL?
Our model-based fair value for Trident Lifeline Ltd is ₹271.05 (as of Nov 17, 2026), built from audited fundamentals. The current price: ₹410.00.
What is the quality score of TLL?
Trident Lifeline Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Trident Lifeline Ltd (TLL)?
Our model-based price target is the fair value of ₹271.05 (as of Nov 17, 2026) from 14 valuation models. Cautious scenario ₹202.64, optimistic scenario ₹353.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Trident Lifeline Ltd stock forecast for 2026?
Our models put fair value at ₹271.05, about 34% lower versus a price of ₹410.00 (overvalued). Cautious scenario ₹202.64, optimistic scenario ₹353.16. The calculation is refreshed regularly with new filings.
What is the revenue of Trident Lifeline Ltd (TLL)?
Trident Lifeline Ltd reported trailing-twelve-month revenue of about ₹1.4B (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Trident Lifeline Ltd (TLL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Trident Lifeline Ltd it is ₹271.05 per share (as of Nov 17, 2026), against a price of ₹410.00. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Trident Lifeline Ltd stock overvalued or undervalued in 2026?
As of Nov 17, 2026, TLL trades above its calculated fair value: price ₹410.00, fair value ₹271.05, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TLL?
No. The price is what the market pays today (₹410.00); the fair value is what the company's own numbers justify (₹271.05). For Trident Lifeline Ltd the two are ₹138.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is Trident Lifeline Ltd worth?
The market values Trident Lifeline Ltd at about ₹4.9B (market capitalisation, as of Nov 17, 2026). Per share that is ₹410.00; our models calculate a fair value of ₹271.05 per share.
What do the bullish and bearish scenarios say about TLL?
Our models span a range for Trident Lifeline Ltd: cautious scenario ₹202.64, base ₹271.05, optimistic ₹353.16 per share (as of Nov 17, 2026, price ₹410.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TLL?
Trident Lifeline Ltd trades at a price-to-earnings ratio of 22.9 (as of Nov 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹271.05 is built from several models across several years. Other multiples: P/B 4.9, P/S 3.5, EV/EBITDA 16.7.
How solid is the balance sheet of Trident Lifeline Ltd (TLL)?
Balance-sheet figures for Trident Lifeline Ltd (as of Nov 17, 2026): return on equity 21.8%, debt of 0.40 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is TLL from its 52-week high?
Trident Lifeline Ltd trades at ₹410.00, about 6% below its 52-week high of ₹434.50 and 72% above the low of ₹237.90 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of ₹271.05 is for.
Which stocks are comparable to Trident Lifeline Ltd?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, Nahdi Medical Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Trident Lifeline Ltd stock attractive at the current price?
The data as of Nov 17, 2026: price ₹410.00, calculated fair value ₹271.05 (−34%), Quality Score 39/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TLL calculated?
We run Trident Lifeline Ltd through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹271.05 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Trident Lifeline Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Trident Lifeline Ltd (TLL)?
The closing price on Nov 19, 2026 was ₹410.00. Our model-based fair value is ₹271.05, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Trident Lifeline Ltd right now?
The price sits above even our optimistic bull case (₹353.16). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Trident Lifeline Ltd

How large is the market capitalisation of Trident Lifeline Ltd (TLL)?
The market capitalisation of Trident Lifeline Ltd is ₹4.9B (≈ $52.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Trident Lifeline Ltd (TLL)?
The price-to-sales ratio of Trident Lifeline Ltd is 3.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Trident Lifeline Ltd (TLL)?
Earnings per share at Trident Lifeline Ltd are ₹17.93 (price ÷ EPS = P/E 22.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Trident Lifeline Ltd (TLL)?
The net margin of Trident Lifeline Ltd is 15.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Trident Lifeline Ltd (TLL)?
The return on equity (ROE) of Trident Lifeline Ltd is 21.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Trident Lifeline Ltd (TLL)?
On an EBIT basis the return on assets of Trident Lifeline Ltd is 10.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Trident Lifeline Ltd (TLL)?
The operating margin of Trident Lifeline Ltd is 20.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Trident Lifeline Ltd (TLL)?
Revenue at Trident Lifeline Ltd is growing 42.8% versus a year earlier (3y avg +59.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Trident Lifeline Ltd (TLL)?
Earnings per share at Trident Lifeline Ltd are growing 74.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Trident Lifeline Ltd (TLL) generate?
The free cash flow of Trident Lifeline Ltd is −₹318M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Trident Lifeline Ltd (TLL) carry?
The net debt of Trident Lifeline Ltd is ₹688M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Trident Lifeline Ltd in the live analysis

One click puts Trident Lifeline Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.